Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gumokimab in active ankylosing spondylitis
NCT05467995Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jun 2021
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gumokimab in ankylosing spondylitis (AS), sponsored by Akeso, Inc.. Started Jun 2021; status: completed.
02
Drugs
gumokimab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05467995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467995.